CME programs

Interventional/Surgery

Aug 22, 2008 11:00 EDT

Traditionally, Latin American countries have had lower rates of PCI and DES use compared with Europe and the US. Recorded at SOLACI 2008, Dr Leon leads an information exchange on PCI north and south of the border with Drs Abizaid, Belardi, Echeverri and Lopez-Cuellar.

Acute Coronary Syndrome

The Science and Medicine of Circulatory Dysfunction and Acute Pressure Syndromes

Aug 18, 2008 09:37 EDT

An investigator and clinical scholar, Dr. Christopher Granger, MD, the program chairman, and his distinguished colleagues illuminate the emerging threats and clinical challenges cardiologists face when managing patients who present with, or undergo, acute, severe, serious, precipitous, and/or life-threatening elevations in systemic blood pressure.

Prevention

Taking the pulse: Understanding CV risk in Type II diabetes

7 COMMENTS - Aug 8, 2008 11:23 EDT

Type 2 diabetes mellitus (T2DM) increases the risk of CVD. What is the role of the cardiologist in helping to reduce CV risk in people with T2DM.

Clinical cardiology

Steering committee

Jul 30, 2008 15:56 EDT

Committee members who steer content development

Hypertension

First response: Improving outcomes - is it all about blood pressure?

1 COMMENT - Jul 25, 2008 11:00 EDT

First hand reports from the joint meeting in Berlin of European Society of Hypertension/ International Society of Hypertension

Prevention

There is a need for effective risk stratification... where do biomarkers fit in?

12 COMMENTS - Jul 17, 2008 09:29 EDT

The majority of physicians agree there is a need for effective risk stratification to enable early, accurate and cost-effective identification of those individuals who would benefit from therapeutic interventions. However, there is a lack of consensus on the use and utility of novel assessment tools that may identify at-risk patients and provide valuable surrogate endpoints. Please share with us your thoughts on the use of biomarkers in clinical care.

Lipid/Metabolic

What are your triglyceride targets?

Jul 14, 2008 09:28 EDT

When and how do you treat elevated triglycerides? Click to take the survey and immediately compare your answers with your colleagues. Your responses will guide us in our selection of topics for future CME programming.

Arrhythmia/EP

Hypertrophic cardiomyopathy (HCM) affects over one million Americans... what do you know about HCM?

6 COMMENTS - Jul 8, 2008 09:00 EDT

Hypertrophic cardiomyopathy (HCM) is a complex but common genetic heart disease that affects nearly one in 500 people in the US and often goes undiagnosed. It is characterized by abnormal thickening of the heart's chamber walls and is the most common cause of sudden cardiac death in people under age 30. Please take a moment to share your perspective on the role of HCM management with theheart.org.

Hypertension

The weight of evidence mounts for ARBs

8 COMMENTS - Jun 30, 2008 16:20 EDT

New trials and more data suggest a more established role for ARBs

Acute Coronary Syndrome

EDICT for ACS: Milestone Practice Advances in STEMI and ACUTE CORONARY SYNDROME

Jun 27, 2008 12:22 EDT

Distinguished faculty members of The Year 2008 EDICT (Emergency Department and Interventional Cardiology Therapeutic teams) for ACS initiative are pleased to invite you to participate in a regional, science-to-strategy summit focused on upstream and downstream management of patients with STEMI and UA/NSTEMI.

Clinical cardiology

Utilization of ICD therapy: The current state of the industry

4 COMMENTS - Jun 27, 2008 10:58 EDT

Dr Eric N Prystowsky MD discusses the current utilization of ICD guidelines and strategies to improve patient care.

Lipid/Metabolic

Examining the effects of CB1 blockade on CAD with IVUS: STRADIVARIUS results

5 COMMENTS - Jun 27, 2008 10:49 EDT

Ongoing interest exists in developing new pharmacologic approaches to address obesity and its sequelae of metabolic risk. Can intravascular ultrasound help us determine if we are on the right track to decreasing atherosclerotic progression with drug therapies? Join us for an insightful interview with Dr. Nissen on the STRADIVARIUS results, the benefits of IVUS and ongoing research examining CB1 blockade and its potential ability to decrease atherosclerotic progression by impacting more than just LDL reduction.

Clinical cardiology

Current trends in cardiac resynchronization therapy

Jun 27, 2008 09:49 EDT

Join Drs Linde, Daubert and Gold in an intriguing discussion on the impact of cardiac resynchronization therapy on remodeling and disease progression, with a review of new data by Dr Abraham.

Hypertension

RAAS inhibition: The foundation for combination therapy

4 COMMENTS - Jun 27, 2008 09:31 EDT

Using combination therapy to achieve better control rates: Does new data from outcome trials suggest a new paradigm?

Prevention

Are you using genetic testing?

6 COMMENTS - Jun 25, 2008 09:30 EDT

Take a second to answer a few polling questions in the Genetics & CV Disease section. Let us know your experience with genetic testing.

Prevention

Human genomics: What does the cardiologist need to know?

9 COMMENTS - Jun 25, 2008 09:30 EDT

Are you hip to SNPs? Dr Eric Topol discusses the identification of genetic variants associated with an increased risk for cardiovascular disease and their potential application to patient management. You can also download Dr Christopher Granger's PowerPoint overview of genetics for the cardiologist.

Clinical cardiology

Thienopyridines in PCI: The lowdown on loading doses

Jun 23, 2008 11:00 EDT

Current guidelines for thienopyridines in PCI note the lack of RCT data for higher loading doses. Read Dr Wang's lowdown on loading doses, including recent presentations from the 2008 SCAI-ACCi2 meeting. Then watch Drs Mehta and Mehran discuss where CURRENT-OASIS-7 will fit in.

Thrombosis Risk

The search for the "ideal" anticoagulant: Where are we now?

6 COMMENTS - Jun 12, 2008 11:00 EDT

Join Drs Turpie, Kakkar, Eriksson and Lassen as they discuss the optimal targets for inhibition in the coagulation cascade and create a "wish list" of characteristics for the ideal oral anticoagulant: Is new clinical trial data realizing that wish?

Lipid/Metabolic

Dyslipidemia and type 2 diabetes: Translating clinical trial data into improving outcomes

13 COMMENTS - Jun 9, 2008 17:47 EDT

Join Drs Frank Sacks, Peter Jones and Theodore Mazzone as they discuss how the results of new clinical trials will affect the treatment of mixed dyslipidemia and reduce cardiovascular risk in patients with type 2 diabetes.

Acute coronary syndromes

Slides and resources

2 COMMENTS - Jun 8, 2008 12:00 EDT

The optimal management of patients with ACS continues to evolve as the data is published and distilled into evidence-based practice. The appropriate utilization of antiplatelet therapies is a critical component. Slides and references with links to abstracts or full text, when available, are provided for ease of access to evidence from randomized trials and outcome studies with antiplatelet therapies.

Interventional/Surgery

Percutaneous treatment of valvular disease

4 COMMENTS - Jun 4, 2008 13:00 EDT

Given the success of PCI, the transcatheter management of cardiac disease has expanded into new frontiers. The area of valvular intervention has rapidly evolved in recent years. Dr Philipp Bonhoeffer, a pioneer in the field, discusses current and future developments in the percutaneous management of valvular disease.

Acute Coronary Syndrome

Optimising outcomes in acute coronary syndromes: role of new approaches to platelet inhibition

5 COMMENTS - Jun 3, 2008 14:22 EDT

Balancing antithrombotic efficacy with risk of bleeding: Join our international panel of experts, Steen Husted, José Carlos Nicolau, Sunil Rao and Robert Storey as they review the mechanisms of platelet activation and emerging evidence from ongoing studies to novel antiplatelet therapies.

Arrhythmia/EP

First response: Late-breaking data on the pharmacologic management of AF

Jun 3, 2008 10:56 EDT

In the ATHENA trial, an investigational amiodarone congener prolonged time to first CV hospitalization or death in elderly AF patients. The electrophysiologists have had their say what are the implications for the rest of the cardiology community? Hear Drs Alpert, Steg and Topol give the non-EP perspective.

Lipid/Metabolic

Medical Crossfire: Hot Topics in Hypercholesterolemia: Impact of Recent Clinical Trial Data on Clinical Practice

May 30, 2008 15:55 EDT

Review data from recent trials on lipid-lowering agents, and evaluate this data within current lipid-lowering strategies to develop an evidence-based strategy for reducing CV risk in patients with hypercholesterolemia. Join Drs Davidson, Jones, and Radar.

Hypertension

A focus on nitric oxide

19 COMMENTS - May 30, 2008 11:16 EDT

Hypertension, hypercholesterolemia, insulin resistance, atherosclerosis, coronary heart disease, heart failure: are they all at the mercy of nitric oxide? Join Drs Weber, Cohn, Mason and Cockcroft in a discussion on the role nitric oxide plays in vascular health.

	Yes
	No